HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Figures Only Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Bottlaender, M. Articles by Ricard, M. Search for Related Content PubMed PubMed Citation Articles by Bottlaender, M. Articles by Ricard, M.

Biodistribution and Radiation Dosimetry of ¹⁸F-Fluoro-A-85380 in Healthy Volunteers

¹ Service Hospitalier Frédéric Joliot, Department of Medical Research, Division of Life Sciences, French Atomic Agency, Orsay, France
² Service de Physique, Institut Gustave Roussy, Villejuif, France

This study reports on the biodistribution and radiation dosimetry of 2-¹⁸F-Fluoro-3-[2(S)-2-azetidinylmethoxy]pyridine (¹⁸F-fluoro-A-85380), a promising radioligand for the imaging of central nicotinic acetylcholine receptors (nAChRs). Methods: Whole-body scans were performed in 3 healthy male volunteers up to 2 h after intravenous injection of 137–238 MBq ¹⁸F-fluoro-A-85380. Transmission scans (3 min per step, 8 or 9 steps according to the height of the subject) in 2-dimensional mode were used for subsequent correction of attenuation of emission scans. Emission scans (1 min per step) were acquired over 2 h. Venous blood samples were taken up to 2 h after injection of the radiotracer. Urine was freely collected up to 2 h after injection of the radiotracer. For each subject, the percentage of injected activity measured in regions of interest over brain, intestine, stomach, bladder, kidneys, and liver were fitted to a monoexponential model, as an uptake phase followed by a monoexponential washout, or to a biexponential model to generate time-activity curves. Using the MIRD method, ten source organs were considered in estimating radiation absorbed doses for organs of the body. Results: Injection of ¹⁸F-fluoro-A-85380 was clinically well tolerated and blood and urine pharmacologic parameters did not change significantly. The primary routes of clearance were renal and intestinal. Ten minutes after injection, high activities were observed in the bladder, kidneys, and liver. Slow uptake was seen in the brain. The liver received the highest absorbed dose. The average effective dose of ¹⁸F-fluoro-A-85380 was estimated to be 0.0194 mSv/MBq. Conclusion: The amount of ¹⁸F-fluoro-A-85380 required for adequate nAChR imaging results in an acceptable effective dose equivalent to the patient.

Key Words: ¹⁸F-fluoro-A-85380 • PET • dosimetry • central nicotinic receptors

This article has been cited by other articles:

				A. G. Mukhin, A. S. Kimes, S. I. Chefer, J. A. Matochik, C. S. Contoreggi, A. G. Horti, D. B. Vaupel, O. Pavlova, and E. A. Stein Greater Nicotinic Acetylcholine Receptor Density in Smokers Than in Nonsmokers: A PET Study with 2-18F-FA-85380 J. Nucl. Med., October 1, 2008; 49(10): 1628 - 1635. [Abstract] [Full Text] [PDF]

				K HERHOLZ, S F CARTER, and M JONES Positron emission tomography imaging in dementia Br. J. Radiol., December 1, 2007; 80(Special_Issue_2): S160 - S167. [Abstract] [Full Text] [PDF]

				B. Le Foll, S. I. Chefer, A. S. Kimes, D. Shumway, S. R. Goldberg, E. A. Stein, and A. G. Mukhin Validation of an Extracerebral Reference Region Approach for the Quantification of Brain Nicotinic Acetylcholine Receptors in Squirrel Monkeys with PET and 2-18F-Fluoro-A-85380 J. Nucl. Med., September 1, 2007; 48(9): 1492 - 1500. [Abstract] [Full Text] [PDF]

				D. R. Sprague, F. T. Chin, J.-S. Liow, M. Fujita, H. D. Burns, R. Hargreaves, J. B. Stubbs, V. W. Pike, R. B. Innis, and P. D. Mozley Human Biodistribution and Radiation Dosimetry of the Tachykinin NK1 Antagonist Radioligand [18F]SPA-RQ: Comparison of Thin-Slice, Bisected, and 2-Dimensional Planar Image Analysis J. Nucl. Med., January 1, 2007; 48(1): 100 - 107. [Abstract] [Full Text] [PDF]

				A. J. Beer, R. Haubner, I. Wolf, M. Goebel, S. Luderschmidt, M. Niemeyer, A.-L. Grosu, M.-J. Martinez, H. J. Wester, W. A. Weber, et al. PET-Based Human Dosimetry of 18F-Galacto-RGD, a New Radiotracer for Imaging {alpha}v{beta}3 Expression J. Nucl. Med., May 1, 2006; 47(5): 763 - 769. [Abstract] [Full Text] [PDF]

				V. Josserand, H. Pelerin, B. de Bruin, B. Jego, B. Kuhnast, F. Hinnen, F. Duconge, R. Boisgard, F. Beuvon, F. Chassoux, et al. Evaluation of Drug Penetration into the Brain: A Double Study by in Vivo Imaging with Positron Emission Tomography and Using an in Vitro Model of the Human Blood-Brain Barrier J. Pharmacol. Exp. Ther., January 1, 2006; 316(1): 79 - 86. [Abstract] [Full Text] [PDF]

				J.-D. Gallezot, M. Bottlaender, M.-C. Gregoire, D. Roumenov, J.-R. Deverre, C. Coulon, M. Ottaviani, F. Dolle, A. Syrota, and H. Valette In Vivo Imaging of Human Cerebral Nicotinic Acetylcholine Receptors with 2-18F-Fluoro-A-85380 and PET J. Nucl. Med., February 1, 2005; 46(2): 240 - 247. [Abstract] [Full Text] [PDF]

				S. Chattopadhyay, B. Xue, D. Collins, R. Pichika, R. Bagnera, F. M. Leslie, B. T. Christian, B. Shi, T. K. Narayanan, S. G. Potkin, et al. Synthesis and Evaluation of Nicotine {alpha}4{beta}2 Receptor Radioligand, 5-(3'-18F-Fluoropropyl)-3-(2-(S)-Pyrrolidinylmethoxy)Pyridine, in Rodents and PET in Nonhuman Primate J. Nucl. Med., January 1, 2005; 46(1): 130 - 140. [Abstract] [Full Text] [PDF]

				D. B. Vaupel, S. R. Tella, D. L. Huso, V. O. Wagner III, A. G. Mukhin, S. I. Chefer, A. G. Horti, E. D. London, A. O. Koren, and A. S. Kimes Pharmacological and Toxicological Evaluation of 2-Fluoro-3-(2(S)-azetidinylmethoxy)pyridine (2-F-A-85380), a Ligand for Imaging Cerebral Nicotinic Acetylcholine Receptors with Positron Emission Tomography J. Pharmacol. Exp. Ther., January 1, 2005; 312(1): 355 - 365. [Abstract] [Full Text] [PDF]